Prognostic significance of cathepsins B and L in primary human breast cancer.

PURPOSE Evaluation of the clinical significance of cytosolic tumor levels of the lysosomal cysteine proteases cathepsin B (catB) and cathepsin L (catL) in patients with primary breast cancer. PATIENTS AND METHODS CatB (n = 1,500) and catL (n = 1,391) levels were determined by enzyme-linked immunosorbent assay (ELISA) in cytosols routinely prepared from frozen-tissue samples that were submitted to our laboratory for the assessment of steroid-hormone-receptor status. The median duration of follow-up of patients still alive at the time of analysis was 93 months. RESULTS Relating catB and catL levels with classical prognostic factors, the proteases were positively correlated with the number of positive lymph nodes (P < .01), and negatively with the level of steroid-hormone receptors (P < .01). We did not find a significant relationship between catB or catL levels with age and menopausal status of the patients or with the size of the primary tumor. The levels of catB and catL were positively correlated with each other and with the rates of relapse and death (all, P < .0001). In multivariate regression analysis for relapse-free survival (RFS) and overall survival (OS), corrected for the contribution of age/menopausal status, tumor size, the number of positive lymph nodes, and steroid-hormone-receptor status, catB and catL were significant predictors of the rates of relapse and death (all, P < .01). No statistically significant interactions of catB or catL with any of the classical prognostic factors or with each other were observed in their associations with the rates of relapse and death. CONCLUSION CatB and catL levels measured in routinely prepared cytosols are strong parameters to predict the rate of relapse and the length of survival after treatment of the primary breast tumor.

[1]  H. Höfler,et al.  Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L. , 1998, Anticancer research.

[2]  N. Harbeck,et al.  Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer. , 1997, British Journal of Cancer.

[3]  M. Duffy,et al.  The urokinase‐type plasminogen activator system in cancer metastasis: A review , 1997, International journal of cancer.

[4]  H. Höfler,et al.  Clinical Impact of the Plasminogen Activation System in Tumor Invasion and Metastasis: Prognostic Relevance and Target for Therapy , 1997, Thrombosis and Haemostasis.

[5]  M. Duffy,et al.  Proteases as prognostic markers in cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  J. Kos,et al.  Lysosomal proteases cathepsins D, B, H, L and their inhibitors stefins A and B in head and neck cancer. , 1995, Biological chemistry Hoppe-Seyler.

[7]  P. Dettmar,et al.  Prognostic value of the cysteine proteases cathepsins B and cathepsin L in human breast cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  V. Turk,et al.  Expression of full-length human procathepsin L cDNA in Escherichia coli and refolding of the expression product. , 1995, Biological chemistry Hoppe-Seyler.

[9]  J. Lindtner,et al.  Prognostic value of total cathepsin B in invasive ductal carcinoma of the breast. , 1995, European Journal of Cancer.

[10]  J. Foekens,et al.  Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  D. Rifkin,et al.  Biology and biochemistry of proteinases in tumor invasion. , 1993, Physiological reviews.

[12]  Robert Gray,et al.  Flexible Methods for Analyzing Survival Data Using Splines, with Applications to Breast Cancer Prognosis , 1992 .

[13]  J. Foekens,et al.  Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. , 1992, Cancer research.

[14]  C. Osborne,et al.  Prognostic factors for breast cancer: have they met their promise? , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Bonnie F. Sloane,et al.  Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. , 1992, The Biochemical journal.

[16]  J. Calvete,et al.  Effective activation of the proenzyme form of the urokinase‐type plasminogen activator (pro‐uPA) by the cysteine protease cathepsin L , 1992, FEBS letters.

[17]  R. Golouh,et al.  Stefins and lysosomal cathepsins B, L and D in human breast carcinoma , 1992, International journal of cancer.

[18]  A. Maseri,et al.  Age Dependence of Ischaemic Heart Syndromes and the Contribution of Haemostatic Deviations , 1992 .

[19]  M. Pagano,et al.  High-performance liquid chromatographic method for the simultaneous purification of cathepsins B, H and L from human liver. , 1991, Journal of chromatography.

[20]  J. Calvete,et al.  Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA). , 1991, The Journal of biological chemistry.

[21]  M. Gottesman,et al.  Expression of cathepsin L in human tumors. , 1991, Cancer research.

[22]  W. L. McGuire,et al.  Breast cancer prognostic factors: evaluation guidelines. , 1991, Journal of the National Cancer Institute.

[23]  Kane Se,et al.  The role of cathepsin L in malignant transformation. , 1990 .

[24]  Bonnie F. Sloane Cathepsin B and cystatins: evidence for a role in cancer progression. , 1990, Seminars in cancer biology.

[25]  T. Maudelonde,et al.  CATHEPSIN D: AN INDEPENDENT PROGNOSTIC FACTOR FOR METASTASIS OF BREAST CANCER , 1989, The Lancet.

[26]  J. Foekens,et al.  Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. , 1989, Cancer research.

[27]  M. Duffy,et al.  Urokinase‐plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report , 1988, Cancer.

[28]  J. Bartek,et al.  Cytochemical and biochemical evidence of cathepsin B in malignant, transformed and normal breast epithelial cells. , 1987, Journal of cell science.

[29]  A. Barrett,et al.  Elastinolytic activity of human cathepsin L. , 1986, The Biochemical journal.

[30]  J. Mort,et al.  Interrelationship of active and latent secreted human cathepsin B precursors. , 1986, The Biochemical journal.

[31]  S. Pocock,et al.  Regression Models and Non‐Proportional Hazards in the Analysis of Breast Cancer Survival , 1984 .

[32]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .